To determine the expression of exoPD-L1, PD-L2 and PD-1 and their soluble free forms from the serum of NSCLC patients, their baseline levels were quantified by multiplexed bead immunoassay. This evidence concerns the gene PDCD1LG2 and non-small cell lung carcinoma.